NCCN Guidelines® Insights - Colon Cancer, Version 2.2018
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation–positive metastatic colorectal cancer with regimens containing vemurafenib.
Target Audience
This activity is designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Colon Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Colon Cancer
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.
INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
Al B. Benson III, MD, Panel Chair, has disclosed that he receives grant/research support from Acerta Pharma; Bristol-Myers Squibb Company; Celgene Corporation; Infi nity Pharmaceuticals; MedImmune Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Taiho Parmaceuticals Co., Ltd. He also receives consulting fees/honoraria from and serves as a scientific advisor for AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim GmbH; Boston Biomedical; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; EMO Serono; Exelixis Inc.; Genentech, Inc.; Guidant Corporation; Halozyme, Inc.; Helsinn Therapeutics; ImmunoGen, Inc.; Lexicon Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Opsona Therapeutics; Pfizer Inc.; Purdue Pharma LP; and Taiho Parmaceuticals Co., Ltd.
Alan P. Venook, MD, Panel Vice Chair, has disclosed that he serves as a scientifi c advisor for Bayer HealthCare; Bristol-Myers Squibb Company; Genentech, Inc.; Merck & Co., Inc.; and Taiho Pharmaceuticals Co., Ltd. He also receives grant/research support from Genentech, Inc., and Merck & Co., Inc.
Stacey Cohen, MD, Panel Member, has disclosed that she has no relevant financial relationships.
Deborah A. Freedman-Cass, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
Pharmacists
National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-18-004-H01-P
All clinicians completing this activity will be issued a certificate of participation.
Available Credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Price
Required Hardware/software
To access this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for article and certificate viewing/printing